Hypertrophic Scars Clinical Trial
— LIBERTIOfficial title:
Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial: The Sequential Multiple Assignment Randomized Trial (SMART) Approach to Treatment of Hypertrophic Burn Scars
Verified date | April 2017 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the efficacy of pulsed dye laser (PDL) and carbon dioxide (CO2) laser in conjunction with usual care (MED) for the treatment of hypertrophic burn scars and will determine the optimal sequence and timing of lasers and usual care.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 99 Years |
Eligibility |
Inclusion Criteria: - have a burn injury which will be at least 6 months old at the time of first treatment, - have one or more symptomatic burn scars (with at least one or more symptoms such as erythema, pruritus, surface irregularity, or tightness not caused by a contracture that would be better served with surgical treatment), - desire laser treatment, - be at least 6 months of age at the time of treatment, - agree to have no aesthetic treatments for their burn scars, such as peels or fillers, until they have completed the study (two-year period), - agree to be randomized into one of the study's treatment conditions, - agree to return for all treatment and follow-up visits for the two-year study period, - agree to refrain from participating in any other treatment-oriented clinical trial for the duration of this study, and - be able and willing to follow the protocol requirements. Exclusion Criteria: - be women who are pregnant or planning to become pregnant during the study, - have had any previous laser treatment of their burn scars, - have open wounds that are not re-epithelialized in the areas of proposed study treatment, - be taking systemic steroids or immunosuppression medication, - have a connective tissue disorder, - be receiving or planning to receive chemotherapy or radiation during the study, - be medically unable to tolerate anesthesia, or - have other conditions that in the opinion of the investigators or clinicians may affect participant safety or compromise study objectives. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Hypotrophic scar score on the Vancouver Scar Scale (VSS) from baseline to three month visit | Baseline and 3 months | ||
Secondary | Long-term hypotrophic scar score on VSS | Two years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00993005 -
CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars
|
Phase 3 | |
Withdrawn |
NCT02546076 -
Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
|
Phase 2 | |
Withdrawn |
NCT01858038 -
Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis
|
N/A | |
Active, not recruiting |
NCT04389619 -
Fractional Microneedling RF vs Intralesional Steroid With & Without Microneedling in Hypertrophic Scars
|
N/A | |
Active, not recruiting |
NCT01113125 -
Scars After Central Venous Catheters
|
Phase 3 | |
Active, not recruiting |
NCT00849004 -
Prevention of Hypertrophic Scars or Keloids
|
N/A | |
Completed |
NCT00142441 -
Effect of Pulse Width on Scar Treatment Using a 595-nm Pulsed Dye Laser
|
N/A | |
Completed |
NCT01078428 -
Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars
|
Phase 4 | |
Completed |
NCT02487212 -
Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery
|
Phase 4 | |
Active, not recruiting |
NCT04532840 -
Effect of Cryotherpy on Hypertrophic Scar
|
Phase 2/Phase 3 | |
Recruiting |
NCT00548210 -
Effectivity of Dermatix in Promoting Scar Maturation
|
Phase 3 |